Abstract
PURPOSE The current trend in ductal carcinoma in situ (DCIS) research is towards treatment de-escalation. Problematically, prognostic indicators for patients at high risk of breast cancer mortality (BCM), rather than recurrence, have not been identified. We aim to identify prognostic factors for the development of metastatic disease and mortality.
EXPERIMENTAL DESIGN Patients diagnosed with DCIS in a local cancer registry as well as in the National Cancer Database (NCDB) and the Surveillance, Epidemiology and End Results (SEER) program were assessed for factors prognostic of metastatic disease, overall, and breast-cancer specific survival. Cox and competing risks regressions were developed.
RESULTS Among 5 patients who developed distant metastatic disease in the cancer registry, 3 had identifiable growth distribution; all 3 were diffuse type. None had in-breast invasive or DCIS recurrences before metastasis. In NCDB and SEER, cumulative incidence of any cause mortality (ACM) and BCM at 10 years was 12%/5.0% for diffuse lesions; 8%/3.6% for patients with microinvasive disease, 7.4%/2.3% for lesions >5 cm, 5.6%/1.4% for lesions 2-5 cm and 5.5%/1.5% for lesions <2 cm. Multivariate hazard ratios for ACM in NCDB and BCM in SEER were 2.0 and 5.3 (p=0.03 and 0.02, respectively). Among patients with diffuse lesions, cumulative incidence ACM at 10 years was 15.0% among those undergoing unilateral mastectomy vs. 2.5% among those undergoing bilateral mastectomy (p=0.11).
CONCLUSION Diffuse DCIS represents an uncommon but deadly subtype for whom treatment escalation, rather than de-escalation, is likely necessary. Further studies elucidating the mechanism of metastasis and best treatment course are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author Olivier Harismendy is supported by grants for other work but none of the authors received funding regarding work presented in this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCSD Human Research Protections Program approved the IRB for the single-institution portion of the study and waived the need for approval for the SEER and NCDB studies as it involved publicly available, deidentified data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Research support: Olivier Harismendy is supported by awards from the National Cancer Institute (U01CA196406 and P30CA023100)
Prior presentations: This study has not been previously presented
Disclaimers: None of the authors have any relevant conflicts of interest to disclose
Data Availability
SEER and NCDB data are maintained by NIH and American College of Surgeons, respectively. Data in the single institution analysis are not publicly available as they contain PHI but the records are obtainable for research parties with IRB approval through the UCSD HRPP.